WallStSmart
VKTX

Viking Therapeutics Inc

NASDAQ: VKTX · HEALTHCARE · BIOTECHNOLOGY

$30.00
-3.78% today

Updated 2026-05-01

Market cap
$3.63B
P/E ratio
P/S ratio
EPS (TTM)
$-3.19
Dividend yield
52W range
$23 – $43
Volume
2.4M

Viking Therapeutics Inc (VKTX) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20122013201420152016201720182019202020212022202320242025
Revenue$0.00$0.00$0.00$0.00$0.00$0.00$10731.00$10701.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)-0.3%-100.0%
Cost of revenue$0.00$0.00$0.00$0.00$0.00$260000.00$277000.00$296000.00$291000.00$292000.00$346000.00$431000.00
Gross profit$0.00$0.00$0.00$0.00$0.00$-260000.00$10731.00$-296000.00$-291000.00$-292000.00$-346000.00$-431000.00
Gross margin100.0%-2766.1%
R&D$275.00$11613.00$22.22M$6.97M$9.00M$13.74M$19.04M$23.56M$31.93M$44.98M$54.23M$63.81M$101.64M$344.95M
SG&A$163.00$89463.00$1.24M$5.03M$4.85M$5.33M$7.12M$9.13M$10.73M$10.70M$16.12M$37.02M$49.28M$48.39M
Operating income$-438.00$-101076.00$-23.47M$-12.00M$-13.85M$-19.07M$-26.16M$-32.69M$-42.66M$-55.68M$-70.36M$-100.83M$-150.92M$-393.34M
Operating margin-397558.5%-520343.9%
EBITDA$-109641.00$-121698.00$-21.26M$-22.39M$1.15M$442882.00$4.66M$-25.37M$3.77M$-55.39M$-70.06M$-100.83M$-150.57M$-393.34M
EBITDA margin35117.9%-517577.8%
EBIT$-110079.00$-101076.00$-23.47M$-11.96M$-12.70M$-18.63M$-21.50M$-25.63M$-39.49M$-55.68M$-70.36M$-100.83M$-150.92M$-393.77M
Interest expense$24549.00$628676.00$1.02M$2.03M$1.95M$562000.00$146000.00$106000.00$18000.00$59000.00$88000.00$94000.00$56000.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-444.00$-146247.00$-21.88M$-23.40M$-14.73M$-20.58M$-22.06M$-25.78M$-39.49M$-54.99M$-68.87M$-85.89M$-109.96M$-359.64M
Net income growth (YoY)-32838.5%-14863.9%-6.9%+37.1%-39.7%-7.2%-16.8%-53.2%-39.2%-25.2%-24.7%-28.0%-227.1%
Profit margin-368045.8%-513877.2%